Target Audience
This activity has been designed for cardiologists, cardiology fellows in training, cardiology nurses, internists, pharmacists, and other physicians interested / involved in the cardiology field.
Need Assessment
The Puerto Rico Chapter of the ACC on its 21st Annual Scientific Meeting is committed to provide the most updated information regarding the management of complex cardiovascular diseases. A well balanced scientific program has been developed emphasizing on new technologies and developments for the management and prevention of cardiovascular disease. The program will meet the real educational needs of internist and cardiologist physicians.
Objectives for the 2010 ACC PR Chapter Scientific Meeting
- Understand the new developments in device therapy
- Recognize the indication for permanent pacemaker lead extraction
- Review the importance of diets, exercise, herbs and supplements in patients with cardiovascular disease
- Review the detection, evaluation and management of women heart disease
- Gain awareness on health information technologies in 2010
- Understand the indications for atrial fibrillation ablation
- Recognize complex cardiac arrhythmias
- Review the diagnosis and management of pulmonary hypertension
- Gain awareness in the concepts of transactional quality and management
- Understand the state and future of the ACC-NCDR
- Review the new antithrombotic therapy for acute coronary syndromes
- Demonstrate how to implement the cardiovascular guidelines into the daily practice.
Faculty Disclosure Policy
It is the policy of Ponce School of Medicine to ensure independence, balance, objectivity, scientific rigor and integrity in all of its sponsored educational activities. All persons who are in a position to control the educational content of a sponsored activity are expected to disclose to the participants any relevant financial relationship(s) they and/or spouse/partner have with the commercial supporters and/or providers of commercial services and/or manufacturers of any commercial products discussed during the educational activity. All conflicts of interest have been identified and resolved prior to the release of this activity.
This activity is jointly sponsored by The Ponce School of Medicine and the Puerto Rico Chapter of the ACC.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Ponce School of Medicine and the Puerto Rico Chapter of the ACC. Ponce School of Medicine is accredited by the ACCME, Provider’s No. 0007249, to provide continuing medical education for physicians. Ponce School of Medicine is accredited by the Puerto Rico Board of Medical Examiners, provider’s No. 016-SE06-TEM
Credit Designation
The Ponce School of Medicine designates this educational activity for a maximum of 20 AMA PRA Category 1 Credit(s)™. Participating physicians, nurses, technicians and pharmacists should only claim credit commensurate with the extent of their participation in the activity.
Americans with Disabilities Act
The Ponce School of Medicine and the Puerto Rico Chapter of the ACC fully comply with the legal requirements of the ADA and rules and regulations thereof.
Statement of Responsibility/Unlabeled Use Disclosure
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions,The Ponce School of Medicine, or the Puerto Rico Chapterof the ACC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Educational Grants Support
This activity is supported in part by an educational grant from:
- AstraZeneca
- Gilead Sciences
- Lilly USA, LLC - For further information concerning Lilly grant funding visit, www.lillygrantoffice.com
- Merck
- Sanofi-Aventis
|
